Biden faces calls to break COVID-19 vaccine patents. Would that boost global supply? CDC: mRNA COVID-19 vaccines highly effective in preventing infections among healthcare workers Humanigen's COVID-19 phase 3 hits goal, sending stock soaring Johnson & Johnson pledges 400M single-dose COVID-19 vaccines to African Union Digital papers, please? New York becomes first state to roll out IBM's digital COVID-19 vaccine passport GlaxoSmithKline, Novavax team up on COVID vaccine production in U.K., helping reduce dependence on AZ shot The top 20 pharma companies by 2020 revenue Biopharma roundup: NeuroRx to submit drug data to FDA Healthcare roundup:” instead of “UPDATED Coronavirus tracker Digital health's top 10 money raisers in 2021 — so far How new insights into COVID's spike protein could guide treatment design Featured Story | By Eric Sagonowsky Some lawmakers are calling on the Biden administration to suspend patent protections on COVID-19 vaccines to help boost supply in other countries. Last week, they took a shot at pitching the idea to White House officials. But breaking patents might not be the best solution, experts say. read more |
| |
|---|
|
Top Stories By Robert King A new study found strong evidence COVID-19 mRNA vaccines from Pfizer and Moderna were highly effective in preventing infections among healthcare workers and other essential personnel. read more By Nick Paul Taylor A phase 3 clinical trial of Humanigen’s lenzilumab in hospitalized COVID-19 patients has met its primary endpoint. Humanigen plans to use the data to seek emergency use authorization from the FDA. read more By Fraiser Kansteiner Johnson & Johnson will provide 400 million doses of its COVID-19 vaccine to Africa, with plans to start deploying 220 million in the third quarter. That's in addition to the 500 million doses J&J aims to distribute to lower-income countries via the World Health Organization's COVAX facility. read more By Andrea Park The race is on to develop a standardized COVID-19 “passport” that will make it easier for businesses and venues to verify a customer’s vaccination or testing status before allowing them entry. First to cross the finish line? IBM and New York state, which launched the Excelsior Pass. read more By Kevin Dunleavy GlaxoSmithKline will help manufacture 60 million COVID-19 vaccine doses for Maryland drugmaker Novavax, which will help relieve the U.K.'s vaccine dependence on AstraZeneca. read more By Eric Sagonowsky The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other, contended with pandemic disruptions—to manufacturing, marketing, R&D and revenue alike. Here's how the year shook out for the top 20 drugmakers by global revenues. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky New data demonstrate the real-world benefits of the Pfizer and Moderna shots. NeuroRx's Zyesami posted positive data in a phase 2/3 trial in critical COVID-19. President Joe Biden is facing calls to break COVID-19 drug and vaccine patents to boost global supply. Plus more. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Heather Landi Three months into 2021 and the explosion of digital health funding shows no signs of abating. So far this year, just 10 companies have raised nearly $2.6 billion. Check out the biggest money raisers in the first quarter of 2021. read more By Arlene Weintraub Researchers at Lehigh University discovered a previously unknown interaction between sugars, or glycans, on the surface of ACE2 receptors and SARS-CoV-2’s spike protein. It may explain why COVID-19 has a higher infection rate than the outbreak caused by SARS-CoV-1 two decades ago, they said. read more | 